Second, pediatric AML patients with fusions involving transcriptional regulators like lysine methyltransferase 2A (KMT2A), CBFA2/RUNX1 translocation partner 3 (CBFA2T3), or motor neuron and pancreas homeobox 1 (MNX1) tend to have few additional mutations and were associated with a particularly poor outcome. This evidence concerns the gene CBFA2T3 and acute myeloid leukemia.